stars 1 stars 2 stars 3

Nanocopoeia is a specialty pharmaceutical company. We solve drug formulation challenges by applying our proprietary ElectroNanospray™ (ENS) platform to; improve the performance of existing drugs, create bioequivalent formulations, and enable formulations for preclinical development. ENS is a novel, patented manufacturing process which produces unique particles that are nano-sized (typically 500 nm to 2 µm), uniform (narrow particle size distribution), and amorphous (non-crystalline). The ENS manufacturing process operates at ambient conditions, utilizes pharmaceutically acceptable excipients and solvents, and is scalable to commercially-relevant batch sizes. The large surface area and amorphous state of the ENS powders results in rapid drug release and enables significantly higher levels of supersaturation, making ENS technology an intriguing new platform for delivering poorly soluble compounds.

Nanocopoeia Questions

The Nanocopoeia annual revenue was $5 million in 2026.

1 people are employed at Nanocopoeia.

Nanocopoeia is based in New Brighton, Minnesota.

The NAICS codes for Nanocopoeia are [3254, 32541, 32, 325].

The SIC codes for Nanocopoeia are [28, 283].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users